Capital Asset Advisory Services LLC Purchases 939 Shares of Johnson & Johnson (NYSE:JNJ)

Capital Asset Advisory Services LLC lifted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 6.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,338 shares of the company’s stock after purchasing an additional 939 shares during the period. Capital Asset Advisory Services LLC’s holdings in Johnson & Johnson were worth $2,896,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Riversedge Advisors LLC boosted its holdings in Johnson & Johnson by 8.6% in the fourth quarter. Riversedge Advisors LLC now owns 3,664 shares of the company’s stock valued at $627,000 after acquiring an additional 289 shares during the last quarter. Hancock Whitney Corp boosted its holdings in Johnson & Johnson by 0.3% in the fourth quarter. Hancock Whitney Corp now owns 65,612 shares of the company’s stock valued at $11,224,000 after acquiring an additional 211 shares during the last quarter. PRW Wealth Management LLC boosted its holdings in Johnson & Johnson by 13.7% in the fourth quarter. PRW Wealth Management LLC now owns 2,385 shares of the company’s stock valued at $408,000 after acquiring an additional 287 shares during the last quarter. Deroy & Devereaux Private Investment Counsel Inc. boosted its holdings in Johnson & Johnson by 7.2% in the fourth quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 8,926 shares of the company’s stock valued at $1,527,000 after acquiring an additional 599 shares during the last quarter. Finally, Hamlin Capital Management LLC boosted its holdings in Johnson & Johnson by 3.5% in the fourth quarter. Hamlin Capital Management LLC now owns 518,653 shares of the company’s stock valued at $88,726,000 after acquiring an additional 17,489 shares during the last quarter. 68.78% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The sale was disclosed in a filing with the SEC, which is available through this link. In other Johnson & Johnson news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares in the company, valued at $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $172.12 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.39 and a debt-to-equity ratio of 0.39. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69. The stock’s 50 day moving average is $176.25 and its 200-day moving average is $174.36. The firm has a market capitalization of $452.92 billion, a price-to-earnings ratio of 25.05, a PEG ratio of 3.48 and a beta of 0.63.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.48 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. The ex-dividend date is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio is 65.79%.

Analyst Ratings Changes

Several brokerages recently commented on JNJ. SVB Leerink reduced their target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday. Raymond James boosted their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. The Goldman Sachs Group boosted their price target on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research note on Tuesday, April 12th. Finally, Citigroup dropped their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $189.89.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.